Myeloma has long been hindered by poor risk stratification and limited testing capabilities as FISH is highly dependent on sample transport and manual processes.
PlasmaSEQ addresses this by enabling testing with as little as 1 nanogram per microliter of DNA, ensuring that physicians can obtain the maximum amount of information from minimal biological material.
With > 500X depth targeted coverage PlasmaSEQ detects mutations in clones as low as 1.3%* points
Comparison with Conventional Diagnostics
A minimum of 2 mL EDTA-anticoagulated bone marrow aspirate is required for PlasmaSEQ testing. Additional specimen types may also be accepted for testing. Please contact our team for specimen eligibility and submission requirements.
Yes. Sample collection kits are available to facilitate PlasmaSEQ testing. Please contact our team to request kits or discuss your specimen collection requirements.
PlasmaSEQ is validated for DNA inputs as low as 1 ng/µL, supporting reliable genomic profiling from low-input specimens while maintaining comprehensive genomic coverage.
PlasmaSEQ can detect clinically relevant genomic alterations that may not be fully characterized by conventional FISH testing, including bi-allelic deletions involving CDKN2C, multi-exonic TP53 deletions, sequence-level mutations, and additional genomic abnormalities associated with multiple myeloma. PlasmaSEQ also evaluates biomarkers relevant to targeted and emerging immunotherapies, providing a more comprehensive genomic profile for risk stratification and therapeutic decision-making.
Yes. PlasmaSEQ can support a variety of research applications. Please contact our team to discuss your research requirements and potential collaboration opportunities.
